Immunovant, Inc.
IMVT
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.2B
$38.65
▼ -2.13%
P/E
-13.80
Mkt Cap
$8.2B
52-Wk Range
$14.58–$45.42
52-Week Range
$14.58 - $45.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 136.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Fully human monoclonal antibody technology with reduced immunogenicity risk
- Selective FcRn inhibition mechanism targeting root cause of autoimmune pathology
- Multi-indication development strategy across large patient populations with high unmet medical need
- Backing from Roivant Sciences providing capital and operational support
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Clinical trial progression in myasthenia gravis and thyroid eye disease with potential for accelerated approval pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+26.8% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying IMVT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.75 vs -$0.63 consensus (-19.3% surprise). Revenue of $7.1M vs $7.1M expected (0.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-19.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q1 27
$0
$0
$0
$0
$0
$0
$0
$7.1M
Margins · last 8Q
Gross
100.0%
Profit
-2159.6%
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
29%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 25, 2026
vs Industry
How IMVT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related